- Home
- DT vs AXSM Comparison
DT vs AXSM Comparison
Compare DT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DT | AXSM |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 9.0B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DT | AXSM |
|---|---|---|
| Price | $39.83 | $158.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 17 |
| Target Price | $52.83 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 5.6M | 510.0K |
| Earning Date | 05-11-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 205.77 | 38.56 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,698,683,000.00 | N/A |
| Revenue This Year | $21.74 | $58.34 |
| Revenue Next Year | $14.85 | $54.30 |
| P/E Ratio | $82.85 | ★ N/A |
| Revenue Growth | ★ 18.75 | N/A |
| 52 Week Low | $33.24 | $86.99 |
| 52 Week High | $57.55 | $191.50 |
Technical Indicators
Market Signals| Indicator | DT | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 38.71 |
| Support Level | $38.50 | $148.14 |
| Resistance Level | $41.62 | $169.11 |
| Average True Range (ATR) | 1.32 | 3.93 |
| MACD | 0.42 | -0.41 |
| Stochastic Oscillator | 90.41 | 32.60 |
Price Performance
Historical ComparisonAbout DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.